Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-29T00:41:47.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Fecal Microbiota Therapy: Ready for Prime Time?

Published online by Cambridge University Press:  10 May 2016

Krishna Rao ,
Vincent B. Young  and
David M. Aronoff
Krishna Rao*
Affiliation:
Department of Internal Medicine, Division of Infectious Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan
Vincent B. Young
Affiliation:
Department of Internal Medicine, Division of Infectious Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan Department of Microbiology and Immunology, University of Michigan School of Medicine, Ann Arbor, Michigan
David M. Aronoff
Affiliation:
Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
*
3120 Taubman Center, 1500 East Medical Center Drive, SPC 5378, Ann Arbor, MI 48109 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
Infection Control & Hospital Epidemiology , Volume 35 , Issue 1 , January 2014 , pp. 28 - 30
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Hurley, BW, Nguyen, CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162(19):2177–2184.Google Scholar
2. Yatsunenko, T, Rey, FE, Manary, MJ, et al. Human gut micro-biome viewed across age and geography. Nature 2012;486(7402): 222–227.CrossRefGoogle Scholar
3. Figueroa, I, Johnson, S, Sambol, SP, Goldstein, EJC, Citron, DM, Gerding, DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012;55(suppl 2):S104–S109.CrossRefGoogle ScholarPubMed
4. McFarland, LV, Elmer, GW, Surawicz, CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97(7):1769–1775.Google Scholar
5. Garey, KW, Ghantoji, SS, Shah, DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rif-aximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011;66(12): 2850–2855.Google Scholar
6. Johnson, S, Gerding, DN. Fidaxomicin “chaser” regimen following vancomycin for patients with multiple C. difficile recurrences. Clin Infect Dis 2012;309–310.Google Scholar
7. Gough, E, Shaikh, H, Manges, AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):994–1002.CrossRefGoogle ScholarPubMed
8. van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013;368(5):407–415.CrossRefGoogle ScholarPubMed
9. Lofgren, ET, Moehring, RW, Anderson, DJ, Weber, DJ, Fefferman, NH. A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013;35:18–27 (in this issue).Google Scholar
10. Chang, JY, Antonopoulos, DA, Kalra, A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197(3):435–438.Google Scholar
11. Young, VB, Schmidt, TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42(3): 1203–1206.Google Scholar
12. Warny, M, Pepin, J, Fang, A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491):1079–1084.Google Scholar
13. Rao, K, Micie, D, Chenoweth, E, et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 2013;61(10):1738–1742.Google Scholar
14. Barbut, F, Petit, JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001;7(8):405–410.Google Scholar
15. Welfare, MR, Lalayiannis, LC, Martin, KE, Corbett, S, Marshall, B, Sarma, JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011;79(4):359–363.CrossRefGoogle ScholarPubMed
16. Besselink, MGH, van Santvoort, HC, Buskens, E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613):651–659.Google Scholar
17. De Leon, LM, Watson, JB, Kelly, CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11(8): 1036–1038.CrossRefGoogle ScholarPubMed
18. Sekirov, I, Russell, SL, Antunes, LCM, Finlay, BB. Gut microbiota in health and disease. Physiol Rev 2010;90(3):859–904.Google Scholar
19. Garrett, WS, Lord, GM, Punit, S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131(1):33–45.Google Scholar